Onconova Therapeutic (ONTX) 3.09 $ONTX Onconova

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Onconova Therapeutic (ONTX) 3.09 $ONTX

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Second Quarter 2016 Financial Results
GlobeNewswire - Mon Aug 15, 6:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the second quarter ended June 30, 2016.
ONTX: 3.09 (-0.16)

Onconova Therapeutics, Inc. Announces Timing for Second Quarter 2016 Financial Results
GlobeNewswire - Thu Aug 11, 8:20AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that financial results for the Company's second quarter ended June 30, 2016 along with recent corporate updates will be released on Monday, August 15, 2016.
ONTX: 3.09 (-0.16)

Onconova Closes Oversubscribed Rights Offering with Gross Proceeds of $17.4 Million
GlobeNewswire - Mon Aug 01, 7:02AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company" , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the closing of its oversubscribed rights offering ("Rights Offering" for aggregate gross proceeds to the Company of approximately $17.4 million, which is the maximum amount allowable under the terms of this Rights Offering.
ONTX: 3.09 (-0.16)

Onconova Presents Clinical Data from Oral Rigosertib and Azacitidine Combination Study in Higher-Risk Myelodysplastic Syndromes at EHA Annual Meeting
GlobeNewswire - Mon Jun 13, 7:07AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data by Onconova collaborators from the U.S. and Europe from the ongoing Phase 2 clinical trial of oral rigosertib in combination with azacitidine in patients with either first- or second-line higher-risk myelodysplastic syndromes (HR-MDS) at the 21 Congress of the European Hematology Association (EHA) in Copenhagen, Denmark, which took place June 9 - 11, 2016.
ONTX: 3.09 (-0.16)

Onconova Announces Presentations Highlighting IV Rigosertib and Oral Rigosertib/Azacitidine Combination at 2016 ASCO Annual Meeting
GlobeNewswire - Mon Jun 06, 4:00PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of data relating to the mechanistic rationale for combining rigosertib with azacitidine at the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held June 3-7 in Chicago, Illinois.
ONTX: 3.09 (-0.16)

Onconova Files S-1 Registration Statement for Rights Offering to Shareholders
GlobeNewswire - Wed Jun 01, 5:30PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX) ("Onconova" or the "Company" , a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced it filed a registration statement on Form S-1 with the Securities and Exchange Commission (the "SEC" for a rights offering to its existing stockholders.
ONTX: 3.09 (-0.16)

Onconova Announces Upcoming Presentations Related to Advanced Rigosertib Clinical Trials at 2016 ASCO Annual Meeting
GlobeNewswire - Tue May 31, 7:45AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced details relating to two poster presentations at the upcoming 2016 American Society of Clinical Oncology Annual Meeting taking place June 3-7 in Chicago, Illinois.
ONTX: 3.09 (-0.16)

Onconova Therapeutics, Inc. Announces Appointment of Jack E. Stover to Board of Directors
GlobeNewswire - Mon May 23, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Jack E. Stover has been appointed to its Board of Directors.
ONTX: 3.09 (-0.16), IDXG: 0.26 (+0.01), PDII: 0.53 (-0.02)

Onconova Therapeutics, Inc. Announces Results of Annual Meeting, Effective Date of One-For-Ten Reverse Stock Split
GlobeNewswire - Fri May 20, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced results from its 2016 annual meeting of stockholders. At the annual meeting, Onconova stockholders voted to approve a reverse stock split of the company's common stock by a ratio of not less than one-for-eight and not more than one-for-twelve. The company's board of directors subsequently fixed the reverse stock split ratio at one-for-ten and fixed the record date for the reverse stock split.
ONTX: 3.09 (-0.16)

Onconova Therapeutics, Inc. Reports Recent Business Highlights and First Quarter 2016 Financial Results
GlobeNewswire - Wed May 11, 3:05PM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a Phase 3 clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the first quarter ended March 31, 2016.
ONTX: 3.09 (-0.16)

Onconova Announces Publication Describing Unique RAS-targeted Mechanism of Action for Rigosertib in the Journal Cell
GlobeNewswire - Thu Apr 21, 6:00PM CDT
-- More than 30% of all human cancers driven by RAS, a target previously considered "undruggable"--
ONTX: 3.09 (-0.16)

Onconova Announces Novel Dual Targeting of ARK5 and CDK4/6 by Pre-clinical Compound, ON 123300, in Presentation at 2016 American Association of Cancer Research (AACR) Annual Meeting
GlobeNewswire - Wed Apr 20, 7:30AM CDT
Onconova Therapeutics, Inc. (Nasdaq:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced the presentation of pre-clinical data for its first-in-class dual inhibitor of ARK5 and CDK4/6 at the 2016 AACR Annual Meeting being held April 16-20, 2016 at the Ernest N. Morial Convention Center in New Orleans, LA.
ONTX: 3.09 (-0.16)

Onconova Therapeutics, Inc. Reports Recent Business Highlights and Year-end 2015 Financial Results
GlobeNewswire - Mon Mar 28, 7:01AM CDT
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today provided a corporate update and reported financial results for the fourth quarter and year-ended December 31, 2015.
ONTX: 3.09 (-0.16)

Onconova Starts Phase III INSPIRE Study on Rigosertib in EU
Zacks Equity Research - Zacks Investment Research - Wed Mar 23, 8:30AM CDT
Onconova (ONTX) initiates patient enrolment in the phase III INSPIRE study on IV rigosertib in the EU.
SHPG: 188.50 (+1.32), ONTX: 3.09 (-0.16), BXLT: 46.02 (-0.18), CELG: 106.37 (-0.37)

Onconova Therapeutics, Inc. Announces Listing Transfer to NASDAQ Capital Market
GlobeNewswire - Thu Feb 04, 4:01PM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it received a positive determination from the NASDAQ Stock Market granting approval of the Company's request to transfer its listing to the NASDAQ Capital Market from the NASDAQ Global Select Market. The Company's securities will begin trading on the NASDAQ Capital Market effective at the start of trading on Friday, February 5, 2016. The Company's shares will continue to trade on NASDAQ under the symbol "ONTX."
ONTX: 3.09 (-0.16)

Essential Thrombocythemia Therapeutics Development Pipeline Review, H2 2015
M2 - Thu Feb 04, 5:00AM CST
Research and Markets (http://www.researchandmarkets.com/research/n57crm/essential) has announced the addition of the "Essential Thrombocythemia - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Essential Thrombocythemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Essential Thrombocythemia and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Essential Thrombocythemia Overview - Therapeutics Development - Pipeline Products for Essential Thrombocythemia - Overview - Pipeline Products for Essential Thrombocythemia - Comparative Analysis - Essential Thrombocythemia - Therapeutics under Development by Companies - Essential Thrombocythemia - Therapeutics under Investigation by Universities/Institutes - Essential Thrombocythemia - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Essential Thrombocythemia - Products under Development by Companies - Essential Thrombocythemia - Products under Investigation by Universities/Institutes - Essential Thrombocythemia - Companies Involved in Therapeutics Development - Aop Orphan Pharmaceuticals AG - Galena Biopharma, Inc. - Incyte Corporation - Italfarmaco S.p.A. - Novartis AG - Onconova Therapeutics, Inc. - PharmaEssentia Corporation For more information visit http://www.researchandmarkets.com/research/n57crm/essential
INCY: 80.81 (-0.29), ONTX: 3.09 (-0.16), GALE: 0.39 (-0.01), NVS: 78.27 (-0.50)

Onconova Therapeutics, Inc. to Present Corporate Update at the 18th Annual BIO CEO & Investor Conference
GlobeNewswire - Mon Feb 01, 7:02AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that Ramesh Kumar, Ph.D., President and Chief Executive Officer, will present a company update at the 18 Annual BIO CEO & Investor Conference in New York, NY. The presentation will take place on Monday, February 8 at 4:00 p.m. ET.
ONTX: 3.09 (-0.16)

Onconova Therapeutics Announces Registered Direct Offering
GlobeNewswire - Wed Jan 06, 7:45AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that it has entered into a definitive agreement with a single institutional investor to receive gross proceeds of approximately $1.84 million.
ONTX: 3.09 (-0.16)

Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015 - Analysis, Technologies & Forecasts
M2 - Wed Dec 23, 3:52AM CST
Research and Markets (http://www.researchandmarkets.com/research/4qgqf3/refractory_anemia) has announced the addition of the "Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015" report to their offering. The clinical trial report, Refractory Anemia With Ringed Sideroblasts Global Clinical Trials Review, H2, 2015" provides an overview of Refractory Anemia With Ringed Sideroblasts clinical trials scenario. This report provides top line data relating to the clinical trials on Refractory Anemia With Ringed Sideroblasts. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Key Topics Covered: - The report provides a snapshot of the global clinical trials landscape - Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status - The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company - The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment - The Report provides enrollment trends for the past five years - Report provides latest news for the past three months Benefits of this Report: - Assists in formulating key business strategies with regards to investment - Helps in identifying prominent locations for conducting clinical trials which saves time and cost - Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities - Supports understanding of trials count and enrollment trends by country in global therapeutics market - Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials - Facilitates clinical trial assessment of the indication on a global, regional and country level Companies Mentioned: - Actinium Pharmaceuticals, Inc. - Syndax Pharmaceuticals, Inc. - SymBio Pharmaceuticals Limited - Onconova Therapeutics, Inc. - Johnson & Johnson - Jaguar Holding Company II - F. Hoffmann-La Roche Ltd. For more information visit http://www.researchandmarkets.com/research/4q...ory_anemia
JNJ: 119.08 (-0.26), ATNM: 1.76 (-0.04), SNDX: 13.94 (-0.24), ONTX: 3.09 (-0.16)

Onconova to Host Myelodysplastic Syndromes (MDS) Key Opinion Leader Meeting on Wednesday, December 16, in New York City
GlobeNewswire - Mon Dec 14, 8:15AM CST
Onconova Therapeutics, Inc. (NASDAQ:ONTX), a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer, today announced that the Company will host a Key Opinion Leader breakfast focused on the treatment landscape for myelodysplastic syndromes (MDS), including the Company's late-stage drug candidate, rigosertib, a small molecule Ras mimetic that inhibits cellular signaling. The event and live webcast will take place on Wednesday, December 16, from 8:00-9:30 AM Eastern Time in New York City.
ONTX: 3.09 (-0.16)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
Kayla Harrison Dominates UFC 334, Earns Big Win

Updated Category News Views 42

Kicking off UFC 334 with a bang, Kayla Harrison didn't just step into the Octagon—she bulldozed her way through Amanda Nunes to retain her Women's Bantamweight Championship. This showdown didn't just electrify New York's Madison Square Garden, it shook the entire MMA landscape. Harrison, the face of Monster Energy's athlete roster, wasn't content with just defending her...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 290

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 343

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 203

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 212

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
Employment Law Suit Hits ABC: Alleged Wage Violations

Updated Category News Views 129

ABC Under Fire for Labor Code Violations You know it's a rocky road when a company like American Broadcasting Companies, Inc. lands itself in hot water with accusations riding high on labor law violations. People yapping about lunch breaks? Well, that’s the ball game here. Meal and Rest Break Controversies According to a recent lawsuit filed by Blumenthal Nordrehaug...

Continue Reading
Princess Cruises Launches New Era at Celebration Key

Updated Category News Views 169

Never thought I'd see the day when a cruise ship docking would stir such excitement, but here we are. The Star Princess has made its grand debut at Celebration Key, the latest jewel in Princess Cruises' crown. And they're going all out with Bahamian flair—something about a Junkanoo band and beach art that would make even the crustiest sailor crack a smile. Inaugural Fun...

Continue Reading

Top 5 Most Recently Viewed Articles

Investors Target Kyverna Therapeutics: Key Details You Need

Updated Category News Views 136

Understanding Ongoing Investigations at Kyverna Therapeutics As the financial landscape continues to evolve, investors find themselves keenly interested in the developments surrounding Kyverna Therapeutics, Inc. (NASDAQ: KYTX). With a prominent law firm engaged in scrutinizing potential claims, the situation promises vital updates for concerned stakeholders. Faruqi &...

Continue Reading
Moody's Upgrades Phillips Edison to Baa2 Rating with Stability

Updated Category News Views 131

Moody's Upgrades Phillips Edison to Baa2 Rating CINCINNATI — Phillips Edison & Company, Inc. (Nasdaq: PECO), a prominent operator of high-quality grocery-anchored neighborhood shopping centers, has recently received an upgrade from Moody's Ratings. The company's issuer credit rating has been raised from 'Baa3' to 'Baa2', reflecting its strong operational performance and...

Continue Reading
Quantum Stocks Soar Amid Rumored Federal Investments

Updated Category News Views 222

Quantum Computing Stocks on the Rise Shares of IonQ Inc. (NYSE: IONQ), Rigetti Computing (NASDAQ: RGTI), and D-Wave Quantum (NYSE: QBTS) have experienced remarkable increases in pre-market trading. IonQ rose by 13.71%, Rigetti by 11.67%, and D-Wave surged by an impressive 15.90%. This surge comes as there are reports suggesting the federal government may be considering...

Continue Reading
Unlocking Success: How a One-Hour Morning Routine Can Transform Lives

Updated Category News Views 384

The Transformative Power of a Screen-Free Morning Jeff Bezos, the visionary behind Amazon, emphasizes the importance of a structured morning without distractions. His approach encourages starting the day without diving into screens, allowing for a calm and focused beginning. Understanding Bezos' Morning Ritual Instead of beginning his day with devices, Bezos opts for...

Continue Reading
Nokia's Strategic Moves: Infinera Acquisition and Stock Insights

Updated Category News Views 186

Nokia's Evolution in Telecom and Network Solutions Nokia Oyj is a global leader in telecom equipment and offers comprehensive network infrastructure solutions. While it once dominated the mobile phone market, Nokia has since repositioned itself as an essential player in the deployment and support of 5G and 4G networks. Its main competitor, Telefonaktiebolaget LM Ericsson,...

Continue Reading